We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
In 2023, Endox had revenues of approximately SEK 65 million
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Divestment is part of BASF’s strategic portfolio optimization
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Subscribe To Our Newsletter & Stay Updated
